Sangeetha Ramsagar’s Post

Going to #Bio2024? Curious about D2R? Meet with Janet Prince, D2R's Senior Industry Liaison Officer, to learn more about D2R's inclusive approach to genomic-based #RNAtherapeutics.

Join us at VALIDATE 2024 for a session you won't want to miss! Alan Murphy and Ian Harley from Alexion Pharmaceuticals, Inc. will be sharing their expertise on innovative applications of Kneat in logbooks, automation, and beyond. 🔍 Session Title: "Unlocking the Potential: Innovative Applications of Kneat in Logbooks, Automation, and Beyond" Alan and Ian will delve into the less "traditional" ways Alexion is leveraging Kneat, including logbooks and automation change processes. But that's not all! They'll also provide a programmatic look at how Kneat is used for different processes, offering valuable insights into their roles, and how they're driving digital validation forward. Don't miss out on this opportunity to gain exclusive insights from industry leaders at Alexion. Register now and secure your spot! https://hubs.ly/Q02syksC0 #VALIDATE #DigitalValidation #Kneat #Innovation #Alexion #Logbooks #Automation #ChangeProcesses #IndustryInsights #ConferenceSession

Achieving better bioprocess scaleup doesn't have to be hard. Join our webinar to learn the steps you can take to scale better, faster, and smarter. https://cytiva.link/ytdnq #biopharma #lifesciences

At #Bio2024? Connect with Josh Brouillette while you are there and learn more about how MedaSystems can support your Expanded Access team.

Achieving better bioprocess scaleup doesn't have to be hard. Join our webinar to learn the steps you can take to scale better, faster, and smarter. https://cytiva.link/ytdnq #biopharma #lifesciences

Achieving better bioprocess scaleup doesn't have to be hard. Join our webinar to learn the steps you can take to scale better, faster, and smarter. https://cytiva.link/ytdnq #biopharma #lifesciences

The Pharma R&D Annual Review 2024 is out now! For over 30 years, Citeline tracked how the climate shifts, revealing the currents and tides shaping the drug development landscape. Download the full report below!

Not sure about your financial position under AN-ACC? Discover how the AN-ACC Accelerator Program can deliver fast results with a clear snapshot of your current resident classifications and options for aligning your funding with rosters. In this blog, Head of Sales, Shannon Sanderson, reveals five powerful ways the AN-ACC Accelerator Program drives outstanding results for our clients. Find our more: https://hubs.la/Q02J1s0Q0 #MakingAgedCareBetter #ANACC #AgedCareAustralia

We're excited to announce that we have today initiated coverage 🔍 📖 on The Craneware Group (#CRW). Craneware is the market leader in value cycle SaaS provision in the US with a 40% market penetration and the ambition to become ubiquitous in US hospitals. The shackles of Covid disruption, digestion of the Sentry acquisition, and the transitioning of its customers to the fully cloud based Trisus platform, have fallen away and opened up new sales opportunities for the group. While the shares have out-performed strongly, multiples look reasonable compared with peers. We calculate a DCF based fair value of 2,541p, 15% above the current share price which could easily prove conservative on stronger medium term revenue growth. Craneware sits in the sweet spot of the structural transformation underway in the US healthcare market to value-based care which is currently also the hottest area of healthcare SaaS M&A activity. If you'd like to learn more about Craneware's story, you can find the note, for free, on the portal on our website, as well as across all the usual platforms such as Bloomberg, Refinitiv, FactSet, Research Tree, etc. below. https://lnkd.in/e9HYn94d Thanks to Colin Smith for the insight, time, and effort! #research #equityresearch #equities #investmentmanagement #capitalmarkets #software #healthcare